SlideShare a Scribd company logo
1 of 12
Improving Measurement of Cognition in
           Pre-MCI Populations
     To Support the API Clinical Trials



         Work supported by Banner Health
       Data from Rush Religious Orders Study

Suzanne B Hendrix, Independent Statistical Consultant
     Contact email: shendrix@pentaracorp.com
API = Alzheimer’s Prevention Initiative

   PS1 Columbian Cohort Data
    – Study started in PS1 carriers
   RUSH Data–Normal progressing to MCI/AD
    – Support for future APOEe4 study
    – Additional data sets for validation
Problem – Ceiling Effects

                        14

                        12
Cognitive Performance




                        10

                        8

                        6
                                   Normal Aging
                        4          Clinical Outcome
                                   Alzheimer's Disease
                        2

                        0
                             -10        -8          -6             -4        -2   0
                                               Years Relative to Diagnosis
Compare Sensitivity to
Decline (MSDR or CV) vs
Normals
                        14
                                                 MSDR=1, CV=1

                        12
Cognitive Performance




                        10

                        8

                        6
                                   Normal Aging
                        4          Clinical Outcome
                                   Alzheimer's Disease
                        2

                        0
                             -10        -8          -6             -4        -2   0
                                               Years Relative to Diagnosis
Compare Sensitivity to
Decline (MSDR or CV) vs
Normals
                        14
                                                MSDR=0.5, CV=2

                        12
Cognitive Performance




                        10

                        8

                        6
                                   Normal Aging
                        4          Clinical Outcome
                                   Alzheimer's Disease
                        2

                        0
                             -10        -8          -6             -4        -2   0
                                               Years Relative to Diagnosis
Compare Sensitivity to
Decline (MSDR or CV) vs
Normals
                        14
                                               MSDR=0.33, CV=3

                        12
Cognitive Performance




                        10

                        8

                        6
                                   Normal Aging
                        4          Clinical Outcome
                                   Alzheimer's Disease
                        2

                        0
                             -10        -8          -6             -4        -2   0
                                               Years Relative to Diagnosis
Compare Sensitivity to
Decline (MSDR or CV) vs
Normals
                        14
                                               MSDR=0.25, CV=4

                        12
Cognitive Performance




                        10

                        8

                        6
                                   Normal Aging
                        4          Clinical Outcome
                                   Alzheimer's Disease
                        2

                        0
                             -10        -8          -6             -4        -2   0
                                               Years Relative to Diagnosis
Best Individual Items – 5 yrs
(converters vs. non-converters)
   Logical Memory IIa (Delayed)
   Category fluency – Fruits
   Logical Memory Ia (Immediate)
   Mini-Mental Status Examination
   Word list memory (Delayed recall)
   Word list recall (Immediate)


All CVs 7.5 to 10 per year and are adjusted for normal aging.
n per group for 1 year study >4000 for detecting a 50% effect
   size with 80% power (even with a population of 100%
   converters at 5 years)
More Items Helps, Then
               Hurts
    (Composite is sum of weighted items)
   Exhaustive Search
   Modeling                               Best Mean to Standard Deviation
                                MSDR
     – Ordinary Least Squares   0.45
                                              Ratio for ADAS-cog Items
       Regression – OLS
                                 0.4
     – Partial Least Squares    0.35
       Regression – PLS
                                 0.3

   Unique items that           0.25

    decline help                 0.2


    Multiple correlated
                                0.15

    sensitive items help
                                 0.1

                                0.05

   Several combinations          0

    give similar sensitivity           1     3     5     7      9
                                                   Number of Items
                                                                     11      13
Potential Items for a Composite
(converters vs. non-converters)
   Good combinations (5 yrs~0.17/yr, n=2160*)
    – East Boston Immediate, Delayed Recall (Logical
      Memory IIa), MMSE, Fruit, Progressive Matrices
    – Ideational Praxis, Delayed
      Recall, Animals, Fruits, Progressive Matrices
   Good combination (2 yrs~0.45/yr, n=315*)
    – Delayed Recall (or LM 1a), Word list memory
      (delayed), Line Orientation, Progressive
      Matrices, Orientation to time

    * Sample size for detecting a 50% effect in a 1 year study with 80% power, alpha 0.05
       Numbers shown for MSDR are “best case” assuming a pure population.
Conclusions

   Composite scores add power over individual
    items – even in pre-MCI population
   Composites need validation for phase 3
   Data based decision making is critical – can
    compare MSDR across studies for same
    populations
   Multiple data sets are also critical for not
    overfitting the data, and for generalizable
    results.
Thanks!
   Banner                          Pentara
    –   Jessica Langbaum             – Stephanie Stanworth
    –   Napatakamon Ayutyanont       – Leah Garriott
    –   Adam Fleisher                – Brian Wells
    –   Pierre Tariot
    –   Eric Reiman
   RUSH
    – David A. Bennett
    – Study Personnel
    – Patients & families

More Related Content

More from Alzforum

First Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTDFirst Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTDAlzforum
 
Protein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and AgingProtein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and AgingAlzforum
 
Lifespan vs. Healthspan
Lifespan vs. HealthspanLifespan vs. Healthspan
Lifespan vs. HealthspanAlzforum
 
Genetic regulation of human brain aging
Genetic regulation of human brain agingGenetic regulation of human brain aging
Genetic regulation of human brain agingAlzforum
 
Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016Alzforum
 
Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016Alzforum
 
Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016Alzforum
 
Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016Alzforum
 
Lary Walker Introduction Webinar
Lary Walker Introduction WebinarLary Walker Introduction Webinar
Lary Walker Introduction WebinarAlzforum
 
Bob Olsson - Alzforum Live Webinar April 29, 2016
Bob Olsson - Alzforum Live Webinar April 29, 2016Bob Olsson - Alzforum Live Webinar April 29, 2016
Bob Olsson - Alzforum Live Webinar April 29, 2016Alzforum
 
Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016Alzforum
 
Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016Alzforum
 
Byron Caughey
Byron CaugheyByron Caughey
Byron CaugheyAlzforum
 
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...Alzforum
 
David Harris -
David Harris - David Harris -
David Harris - Alzforum
 
Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?Alzforum
 
Virginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological TauVirginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological TauAlzforum
 
The cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's diseaseThe cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's diseaseAlzforum
 
Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted Alzforum
 
Cliff Brangwynne
Cliff BrangwynneCliff Brangwynne
Cliff BrangwynneAlzforum
 

More from Alzforum (20)

First Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTDFirst Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTD
 
Protein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and AgingProtein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and Aging
 
Lifespan vs. Healthspan
Lifespan vs. HealthspanLifespan vs. Healthspan
Lifespan vs. Healthspan
 
Genetic regulation of human brain aging
Genetic regulation of human brain agingGenetic regulation of human brain aging
Genetic regulation of human brain aging
 
Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016
 
Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016
 
Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016
 
Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016
 
Lary Walker Introduction Webinar
Lary Walker Introduction WebinarLary Walker Introduction Webinar
Lary Walker Introduction Webinar
 
Bob Olsson - Alzforum Live Webinar April 29, 2016
Bob Olsson - Alzforum Live Webinar April 29, 2016Bob Olsson - Alzforum Live Webinar April 29, 2016
Bob Olsson - Alzforum Live Webinar April 29, 2016
 
Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016
 
Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016
 
Byron Caughey
Byron CaugheyByron Caughey
Byron Caughey
 
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
 
David Harris -
David Harris - David Harris -
David Harris -
 
Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?
 
Virginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological TauVirginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological Tau
 
The cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's diseaseThe cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's disease
 
Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted
 
Cliff Brangwynne
Cliff BrangwynneCliff Brangwynne
Cliff Brangwynne
 

Hendrix Alzforum Feb 28 2013 final

  • 1. Improving Measurement of Cognition in Pre-MCI Populations To Support the API Clinical Trials Work supported by Banner Health Data from Rush Religious Orders Study Suzanne B Hendrix, Independent Statistical Consultant Contact email: shendrix@pentaracorp.com
  • 2. API = Alzheimer’s Prevention Initiative  PS1 Columbian Cohort Data – Study started in PS1 carriers  RUSH Data–Normal progressing to MCI/AD – Support for future APOEe4 study – Additional data sets for validation
  • 3. Problem – Ceiling Effects 14 12 Cognitive Performance 10 8 6 Normal Aging 4 Clinical Outcome Alzheimer's Disease 2 0 -10 -8 -6 -4 -2 0 Years Relative to Diagnosis
  • 4. Compare Sensitivity to Decline (MSDR or CV) vs Normals 14 MSDR=1, CV=1 12 Cognitive Performance 10 8 6 Normal Aging 4 Clinical Outcome Alzheimer's Disease 2 0 -10 -8 -6 -4 -2 0 Years Relative to Diagnosis
  • 5. Compare Sensitivity to Decline (MSDR or CV) vs Normals 14 MSDR=0.5, CV=2 12 Cognitive Performance 10 8 6 Normal Aging 4 Clinical Outcome Alzheimer's Disease 2 0 -10 -8 -6 -4 -2 0 Years Relative to Diagnosis
  • 6. Compare Sensitivity to Decline (MSDR or CV) vs Normals 14 MSDR=0.33, CV=3 12 Cognitive Performance 10 8 6 Normal Aging 4 Clinical Outcome Alzheimer's Disease 2 0 -10 -8 -6 -4 -2 0 Years Relative to Diagnosis
  • 7. Compare Sensitivity to Decline (MSDR or CV) vs Normals 14 MSDR=0.25, CV=4 12 Cognitive Performance 10 8 6 Normal Aging 4 Clinical Outcome Alzheimer's Disease 2 0 -10 -8 -6 -4 -2 0 Years Relative to Diagnosis
  • 8. Best Individual Items – 5 yrs (converters vs. non-converters)  Logical Memory IIa (Delayed)  Category fluency – Fruits  Logical Memory Ia (Immediate)  Mini-Mental Status Examination  Word list memory (Delayed recall)  Word list recall (Immediate) All CVs 7.5 to 10 per year and are adjusted for normal aging. n per group for 1 year study >4000 for detecting a 50% effect size with 80% power (even with a population of 100% converters at 5 years)
  • 9. More Items Helps, Then Hurts (Composite is sum of weighted items)  Exhaustive Search  Modeling Best Mean to Standard Deviation MSDR – Ordinary Least Squares 0.45 Ratio for ADAS-cog Items Regression – OLS 0.4 – Partial Least Squares 0.35 Regression – PLS 0.3  Unique items that 0.25 decline help 0.2 Multiple correlated 0.15  sensitive items help 0.1 0.05  Several combinations 0 give similar sensitivity 1 3 5 7 9 Number of Items 11 13
  • 10. Potential Items for a Composite (converters vs. non-converters)  Good combinations (5 yrs~0.17/yr, n=2160*) – East Boston Immediate, Delayed Recall (Logical Memory IIa), MMSE, Fruit, Progressive Matrices – Ideational Praxis, Delayed Recall, Animals, Fruits, Progressive Matrices  Good combination (2 yrs~0.45/yr, n=315*) – Delayed Recall (or LM 1a), Word list memory (delayed), Line Orientation, Progressive Matrices, Orientation to time * Sample size for detecting a 50% effect in a 1 year study with 80% power, alpha 0.05 Numbers shown for MSDR are “best case” assuming a pure population.
  • 11. Conclusions  Composite scores add power over individual items – even in pre-MCI population  Composites need validation for phase 3  Data based decision making is critical – can compare MSDR across studies for same populations  Multiple data sets are also critical for not overfitting the data, and for generalizable results.
  • 12. Thanks!  Banner  Pentara – Jessica Langbaum – Stephanie Stanworth – Napatakamon Ayutyanont – Leah Garriott – Adam Fleisher – Brian Wells – Pierre Tariot – Eric Reiman  RUSH – David A. Bennett – Study Personnel – Patients & families